US 11186873
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
granted A61KA61K31/404A61K31/7088
Quick answer
US patent 11186873 (Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)) held by Wellmarker Bio Co., LTD. expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Wellmarker Bio Co., LTD.
- Grant date
- Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/404, A61K31/7088, A61K31/713, A61P